Indeed, good clinical response to TNF‐blockers was observed in RA patients with myeloid synovial phenotype, whereas the clinical response to IL‐6 receptor blocker tocilizumab was detected in the lymphoid synovial phenotype [17]. Here, TNF is linked to rheumatoid arthritis.